Make the most of 2020. Read the FT in print for just $99.
Add this topic to your myFT Digest for news straight to your inbox
Investors in a pioneering fund should brace themselves for a rollercoaster ride
Similar products in North America have proved popular despite a poor year for the sector
Insurers remain cautious in taking on risk, resulting in higher premiums
Momentum has stalled in key markets such as New York, New Jersey and Connecticut
Pot price falls and inventories grow as legal and illicit markets compete for customers
Promises of huge growth are yet to materialise — but there’s huge potential
Secret Buckinghamshire warehouse can store enough cannabis to supply 5,000 patients a month
The non-transparent and actively managed ETFs that are luring asset managers. Plus: the rush into marijuana funds; bond investors weigh the merits of ETFs; a China-Japan ‘feeder’ fund scheme; and the struggle to get through to retail investors
Small issuers grab early mover advantage while others worry over legal risks
Some investors fear prosecution under anti-money laundering legislation
Demand for cannabidiol could see the market expand to $20bn in 5 years
Canadian pioneer faces big risks and even bigger opportunities
In cases of intractable epilepsy, cannabidiol can be the only effective treatment. Why is it so hard to obtain?
Surge of greenfield FDI as country exploits competitive edge
From the DJ activist Chelsea Leyland to the CBD start-ups, the stoner sisterhood is leading the charge for the marijuana movement
Maker of Gauloises cigarettes strikes £75m deal with Canada’s Auxly
Hong Kong protesters target China’s main government offices in the territory
The country has land, sun and skilled workers, but it must also deliver on medicinal-grade quality
Market forecast to reach £16.5bn in the next decade
Co-chief executive to stand down as board seeks leader for ‘next phase of growth’
State advisory body says monopoly would raise as much as €2.8bn in tax receipts
Recreational cannabis draws more than double the investments in medical
£12.6bn investment portfolios to remove across-the-board ban on marijuana
Strict laws mean that drink and tobacco companies are staying clear of nascent sector
Drinks group eyes new routes to growth as US-Japanese integration woes ease
